In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells

Downregulation of Leukocyte Migration After Treatment With CCR5 Antagonist Maraviroc

(2010) Raffaella Rossi et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

When and how to use maraviroc in HIV-infected patients

(2009) Vincent Soriano et al.   AIDS

CCR5 antagonism in HIV infection: ways, effects, and side effects

(2009) Pierre Corbeau et al.   AIDS

Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy

(2009) Benoît Marin et al.   AIDS

HIV interactions with monocytes and dendritic cells: viral latency and reservoirs

(2009) Christopher M Coleman et al.   Retrovirology

Myeloid cells in atherosclerosis: initiators and decision shapers

(2009) Oliver Soehnlein et al.   Seminars in Immunopathology

The biology of CCR5 and CXCR4

(2009) Ghalib Alkhatib   Current Opinion in HIV and AIDS

Safety concerns about CCR5 as an antiviral target

(2009) Amalio Telenti   Current Opinion in HIV and AIDS

Optimal use of maraviroc in clinical practice

(2008) Vincent Soriano et al.   AIDS

Increased carotid intima media thickness is associated with depletion of circulating myeloid dendritic cells in HIV-infected patients on suppressive antiretroviral treatment

(2008) Miriam Lichtner et al.   ATHEROSCLEROSIS

Reviews Of Anti‐infective Agents: Maraviroc: The First of a New Class of Antiretroviral Agents

(2008) Rodger D. MacArthur et al.   CLINICAL INFECTIOUS DISEASES

Maraviroc: A CCR5-receptor antagonist for the treatment of HIV-1 infection

(2008) Sharon S. Lieberman-Blum et al.   CLINICAL THERAPEUTICS

Plasmacytoid Dendritic Cells Count in Antiretroviral-Treated Patients is Predictive of HIV Load Control Independent of CD4+ T-Cell Count

(2008) Claudio Mastroianni et al.   CURRENT HIV RESEARCH

Roles of MCP-1 in development of HIV-dementia

(2008) Navneet Kaur Dhillon   Frontiers in Bioscience-Landmark

Genetic Deficiency of Chemokine Receptor CCR5 Is a Strong Risk Factor for Symptomatic West Nile Virus Infection: A Meta‐Analysis of 4 Cohorts in the US Epidemic

(2008) Jean K. Lim et al.   JOURNAL OF INFECTIOUS DISEASES